CON# IDIQ-NHLBI-TOPMED-CORE
    Sponsoring Agency HHS
    POP 9/26/16 - 9/25/21 (4 years)

Description

NHLBI's Trans-Omics for Precision Medicine (TOPMed) program seeks to discover factors that influence disease risk, identify subtypes of disease, and develop more targeted and personalized treatments. NHLBI's Centralized Omic REsource (CORE) program provides whole genome sequencing and other Omics measures including DNA methylation, RNA expression patterns and metabolic profiling for use with other phenotype and clinical outcome data from studies focused on HLBS disorders. Thus the program in conjunction with NHLBI's TOPMed Program, seeks to discover factors that influence disease risk, identify subtypes of disease, and develop more targeted and personalized treatments. In addition to providing a comprehensive view of genetic, molecular, and cellular architecture, the unprecedented rich data resource generated by CORE will be available to the scientific community stimulating innovative approaches to examine novel questions to address HLBS disorders.

  • $80.9m Aggregate Dollars Obligated
  • $80.9m Aggregate Base & Exercised Options
  • $80.9m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts